Directors of the NCI, NIH and commissioner of the FDA to address symposium on cancer diagnostics

AdvaMedDx and the American Association for Cancer Research (AACR) will hold a joint symposium on transforming cancer care through diagnostics and personalized medicine all day Tuesday, Oct. 29, at the Grand Hyatt in Washington.

Harold Varmus, MD, director of the National Cancer Institute, will discuss the state of cancer care during the morning keynote session. Francis Collins, MD, PhD, director of the National Institutes of Health, and Margaret Hamburg, MD, commissioner of the U.S. Food and Drug Administration, will discuss personalized medicine during the afternoon keynote session. Additional session topics will cover: advances in genomics; detection and prognosis; patient safety and innovation; and ensuring patient access to innovative diagnostics.About

AdvaMedDx:
AdvaMedDx represents the world’s leading diagnostics manufacturers to advocate for the power of medical diagnostic tests to promote wellness, improve patient outcomes, and advance public health in the United States and abroad. AdvaMedDx member companies produce innovative, safe and effective diagnostic tests. These tests facilitate evidence-based medicine, improve quality of care, promote wellness, enable early detection of disease and often reduce health care costs. For more information about AdvaMedDx, visit http://advameddx.org/.
 
About AACR:
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.